Literature DB >> 18492725

AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression.

S Chourbaji1, M A Vogt, F Fumagalli, R Sohr, A Frasca, C Brandwein, H Hörtnagl, M A Riva, R Sprengel, P Gass.   

Abstract

Recent evidence indicates that glutamate homeostasis and neurotransmission are altered in major depressive disorder, but the nature of the disruption and the mechanisms by which it contributes to the syndrome are unclear. Glutamate can act via AMPA, NMDA, or metabotropic receptors. Using targeted mutagenesis, we demonstrate here that mice with deletion of the main AMPA receptor subunit GluR-A represent a depression model with good face and construct validity, showing behavioral and neurochemical features of depression also postulated for human patients. GluR-A(-/-) mice display increased learned helplessness, decreased serotonin and norepinephrine levels, and disturbed glutamate homeostasis with increased glutamate levels and increased NMDA receptor expression. These results correspond well with current concepts regarding the role of AMPA and NMDA receptors in depression, postulating that compounds that augment AMPA receptor signaling or decrease NMDA receptor functions have antidepressant effects. GluR-A(-/-) mice represent a model to investigate the pathophysiology underlying the depressive phenotype and to identify changes in neural plasticity and resilience evoked by the genetic alterations in glutamatergic function. Furthermore, GluR-A(-/-) mice may be a valuable tool to study biological mechanisms of AMPA receptor modulators and the efficacy of NMDA antagonists in reducing behavioral or biochemical changes that correlate with increased helplessness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492725     DOI: 10.1096/fj.08-106450

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  48 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Gislaine T Rezin; Daiane B Fraga; Juliana F Daufenbach; Giselli Scaini; Joana Benedet; Natália Rochi; Emílio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-09-28       Impact factor: 3.575

3.  VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine.

Authors:  Cheng Jiang; Wei-Jye Lin; Benoit Labonté; Carol A Tamminga; Gustavo Turecki; Eric J Nestler; Scott J Russo; Stephen R Salton
Journal:  Neuropsychopharmacology       Date:  2018-11-20       Impact factor: 7.853

Review 4.  Neuroinflammation and comorbidity of pain and depression.

Authors:  A K Walker; A Kavelaars; C J Heijnen; R Dantzer
Journal:  Pharmacol Rev       Date:  2013-12-11       Impact factor: 25.468

Review 5.  From synapse to nucleus: novel targets for treating depression.

Authors:  Herbert E Covington; Vincent Vialou; Eric J Nestler
Journal:  Neuropharmacology       Date:  2009-12-17       Impact factor: 5.250

6.  Calcium-permeable AMPA receptors in the nucleus accumbens regulate depression-like behaviors in the chronic neuropathic pain state.

Authors:  Yossef Goffer; Duo Xu; Sarah E Eberle; James D'amour; Michelle Lee; David Tukey; Robert C Froemke; Edward B Ziff; Jing Wang
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

Review 7.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?

Authors:  Paul J Fitzgerald; Chris Barkus; Michael Feyder; Lisa M Wiedholz; Yi-Chyan Chen; Rose-Marie Karlsson; Rodrigo Machado-Vieira; Carolyn Graybeal; Trevor Sharp; Carlos Zarate; Judith Harvey-White; Jing Du; Rolf Sprengel; Peter Gass; David Bannerman; Andrew Holmes
Journal:  Neurobiol Dis       Date:  2010-08-08       Impact factor: 5.996

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.